The MOTS-c discussion carried forward the same questions raised by BPC-157, KPV, and TB-500: what evidentiary standard applies under Section 503A, how much weight should be given to physician experience and real-world use, and whether FDA is evaluating the substance itself or the limitations of an incomplete nomination.
MOTS-c may have one of the stronger biological rationales among the substances reviewed. MOTS-c is a naturally occurring mitochondrial-derived peptide made up of 16 amino acids; the substances reviewed for compounding were synthetic MOTS-c free base and MOTS-c acetate. In simpler terms, it is produced by the part of the cell responsible for managing energy and has been studied for its potential role in glucose regulation, metabolism, muscle function, exercise response, and age-related decline.
Much of that evidence remains laboratory and animal based. The human evidence highlighted during public comment involved CB4211, a modified analog of MOTS-c. During Committee questioning, FDA confirmed that it located a conference poster and oral abstract describing a Phase 1 study, but emphasized that CB4211 is a different substance from MOTS-c free base and MOTS-c acetate. The analog data may inform the broader biological discussion, but they do not directly establish the safety, dosing, or effectiveness of the substances under review.
FDA stated that it did not identify publicly available human studies involving administration of MOTS-c free base or acetate. The agency also found no direct human pharmacokinetic data, established dosing, nonclinical toxicity studies, or human studies addressing immunogenicity or aggregation.
FDA’s characterization concerns again flowed heavily from the withdrawn nomination. The submission identified MOTS-c free base, while the certificate of analysis related to MOTS-c acetate. FDA also identified missing information involving impurities, aggregation, microbial contamination, bacterial endotoxins, and solubility for products proposed as subcutaneous injections.
USP sharpened that concern during the Committee discussion. The nomination proposed five- and ten-milligram injectable products but did not clearly establish whether those amounts referred to the free base or acetate. Solubility information was unavailable for the free base, and USP questioned whether the proposed products could be reliably formulated and tested. USP also identified missing information involving particulate matter, endotoxins, and other quality attributes expected for injectable products.
Public commenters did not ask the Committee simply to disregard those gaps. They argued that the absence of a regulated pathway does not eliminate existing use.
One physician summarized the case for inclusion clearly: “A decision to list MOTS-c does not create demand that is not there. It gives existing use a quality floor.”
Supporters argued that the policy choice was not whether MOTS-c would exist in the marketplace, but whether some portion of that use could occur through licensed prescribers and pharmacies applying identifiable sourcing, testing, and accountability standards.
An analytical chemist reported that roughly two-thirds of the MOTS-c samples tested from the research-use-only market fell outside label claim. Some were reportedly overpotent, one contained no quantifiable MOTS-c, and two contained undisclosed trifluoroacetic acid, or TFA.
His standard was direct: “No confirmation means no match, means no release.”
Commenters also proposed Drug Master Files, satisfactory FDA inspections of API manufacturers, independent third-party testing, and defined specifications for identity, potency, purity, impurities, endotoxins, sterility, and TFA. They also proposed complete batch records, retained samples, process revalidation, physician monitoring, and adverse-event reporting.
The Committee’s questions exposed a central limitation in that proposed pathway. FDA stated that it does not have authority to require 503A pharmacies to report adverse events. When a member asked whether enhanced safety surveillance could become part of the process, FDA explained that congressional action would be required. FDA contrasted that with the Investigational New Drug pathway, where formal safety collection and adverse-event reporting would be mandatory, including under a research IND.
That limitation cuts both ways. Opponents argued that it shows the proposed guardrails cannot be guaranteed. Supporters can fairly respond that a limitation in FDA’s statutory authority does not itself establish that MOTS-c should be excluded—particularly where pharmacies, prescribers, manufacturers, accreditation organizations, and state boards may still adopt stronger standards within their respective authority.
The Committee also questioned whether Bulks List inclusion could be confused with FDA approval, particularly after the widespread public exposure to compounded GLP-1 products. FDA acknowledged that this was a valid concern and noted that some telehealth platforms have falsely represented compounded products as FDA approved or generic. FDA and the Federal Trade Commission have authority to address false or misleading advertising, but FDA also acknowledged that its enforcement resources are limited.
FDA separately clarified that the Committee was not voting on whether to place MOTS-c in Category 1. Category 1 was an interim enforcement-discretion designation, not placement on the statutory 503A Bulks List. FDA stated that these peptides had never been in Category 1 and had been placed in Category 2 in 2023. The question before the Committee was whether the substances should now be added to the Bulks List through rulemaking.
The most supportable case for inclusion was therefore not that the CB4211 study proves MOTS-c free base or acetate is safe and effective. It does not. The case was that MOTS-c has a meaningful biological foundation, early human evidence involving a modified analog, reported physician and pharmacy experience, and analytical methods capable of creating a measurable quality floor.
For MOTS-c free base, the Committee ultimately voted 7–5, with two abstentions, in favor of recommending inclusion.
Members voting no focused on the lack of direct clinical safety and effectiveness data, the injectable route, insufficient physical and chemical characterization, broad or unclear proposed uses, and the absence of fundamental information needed to determine how the substance should be used.
The affirmative votes generally reflected support for prescriber-directed compounding through licensed pharmacies and interest in developing a more accountable safety-reporting framework. One pharmacist voting yes emphasized the apparent willingness of 503A pharmacies to participate in adverse-event reporting and urged the Committee and FDA to explore how they could help create that system. Another member emphasized the need for clearer public education about the difference between Category 1, Bulks List inclusion, and FDA drug approval.
The two abstentions also reflected different concerns. The National Association of Boards of Pharmacy liaison maintained the organization’s neutral position on peptide inclusion. A physician abstained because the evidence remained limited and the potential for immunogenicity could not be resolved, even though the substance appeared to have clinical potential.
The narrow vote captured the central divide. Supporters saw an opportunity to move existing use toward prescriber oversight and measurable quality standards. Opponents saw an injectable substance without enough direct human data or enforceable surveillance to justify opening the pathway.
The question was not whether the record was complete. It was whether the current gaps required exclusion—or whether a regulated pathway could establish a quality floor while better evidence and safety infrastructure continue to develop.